NEW YORK (GenomeWeb News) — Shares in Vermillion, formerly Ciphergen Biosystems, were up 9.3 percent, or $.08, at $.94 in mid-afternoon trading today after the company published findings showing how a protein biomarker may help diagnose peripheral artery disease.
 
Specifically, the findings suggest that the biomarker, called beta-2 microglobulin, is elevated in patients with PAD and that the level of the protein is correlated with the severity of the disease.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.